Table 1

Characteristics for Swedish patients with RA starting a second TNFi (INF, ETA or ADA) during 2006–2012 at the time-point of their second TNFi start

INF
N=74
ETA
N=448
ADA
N=430
Difference among groups (p value)Post hoc comparisons between groups
Age in years (mean±SD)52.7±15.0
(74)
53.8±13.0
(448)
54.4±13.4
(430)
0.56
Sex (% female)77.0%
(74)
77.0% [448)77.2%
(430)
0.99
Disease duration (median, IQR)9.9 (3.2–15.1)
(67)
8.4 (3.7–15.9)
(408)
8.6 (4.3–16.8)
(381)
0.66
RF (% positive)85.9%
(71)
81.1%
(429)
74.6%
(410)
0.02INF vs ADA
ETA vs ADA
Baseline DAS28 (mean±SD)5.0±1.3
(59)
5.1±1.4
(372)
4.7±1.4
(335)
0.001ETA vs ADA
Baseline HAQ (mean±SD)1.2±0.7
(63)
1.2±0.6
(385)
1.1±0.6
(363)
0.38
Concomitant DMARDs (% yes)86.5%
(74)
76.8%
(448)
69.5%
(430)
0.002INF vs ADA
ETA vs ADA
Concomitant MTX (%)82.4%65.0%59.5%0.001INF vs ETA
INF vs ADA
ETA vs ADA
Concomitant Glucocorticoids (% yes)41.9%
(74)
52.9%
(448)
50.5%
(430)
0.21
  • Number in brackets indicates the number of patients with available information for each variable. One-way analysis of variance was used to compare continuous variables followed by Bonferroni test for post hoc comparisons between the groups, while χ² test was used for nominal variables. Kruskal–Wallis test was used to compare non-normally distributed continues variables across groups.

  • ADA, adalimumab; DAS28, disease activity score based on 28-joint status; DMARD, disease modifying antirheumatic drug; ETA, etanercept; HAQ, health assessment questionnaire; INF, infliximab; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; TNFi, tumour necrosis factor inhibitor.